Detecting & Differentiating Ovarian Cancer Earlier
Our Research
Promising Evidence for Women with Pelvic Masses
Published in the journal Clinical Cancer Research in Dec 2023, our methods and flagship test OvaPrint TM demonstrated best in class sensitivity and specificity for detecting ovarian cancer in early stages and differentiating between High Grade Serous Ovarian Cancer and benign tumors. This study demonstrates the potential for OvaPrint to be a test for symptomatic and asymptomatic women in the general population.
There is no reliable screening test that detects early-stage ovarian cancer when it's easiest to treat and the survival rates are higher. It's an unmet need for women and clinicians alike.
Bodour Salhia PhD, Founder
